iomeprol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1463	78649-41-9

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iomeprol
iomeron
imeron

Molecular weight: 777.09
Formula: C17H22I3N3O8
CLOGP: -2.31
LIPINSKI: 3
HAC: 11
HDO: 7
TPSA: 179.66
ALOGS: -3.12
ROTB: 10

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rash maculo-papular	198.70	64.39	50	668	31846	63456458
Toxic skin eruption	168.98	64.39	37	681	12848	63475456
Acute generalised exanthematous pustulosis	168.76	64.39	36	682	11063	63477241
Drug reaction with eosinophilia and systemic symptoms	166.51	64.39	44	674	33792	63454512
Eosinophilia	128.19	64.39	33	685	22723	63465581

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	316.20	73.88	78	492	32934	34923427
Rash maculo-papular	140.15	73.88	40	530	28411	34927950
Acute kidney injury	107.68	73.88	64	506	304924	34651437
Toxic skin eruption	93.38	73.88	24	546	11361	34945000
Acute generalised exanthematous pustulosis	89.69	73.88	21	549	6755	34949606

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	466.69	58.80	122	1164	64122	79678980
Rash maculo-papular	328.10	58.80	90	1196	55988	79687114
Toxic skin eruption	253.98	58.80	61	1225	22232	79720870
Acute generalised exanthematous pustulosis	247.92	58.80	57	1229	17197	79725905
Eosinophilia	167.21	58.80	51	1235	45294	79697808
Acute kidney injury	129.88	58.80	88	1198	519316	79223786
Rash morbilliform	70.66	58.80	17	1269	6133	79736969

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB10	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37338	contrast media
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.56	acidic
pKa2	11.03	acidic
pKa3	11.52	acidic
pKa4	13.95	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01719	KEGG_DRUG
C0063810	UMLSCUI
CHEBI:31710	CHEBI
CHEMBL2107214	ChEMBL_ID
DB11705	DRUGBANK_ID
C057937	MESH_SUPPLEMENTAL_RECORD_UI
5859	INN_ID
17E17JBP8L	UNII
3731	PUBCHEM_CID
2606484	RXNORM
19468	MMSL
d05472	MMSL
006219	NDDF
356671000	SNOMEDCT_US
395753004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-7250	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-7300	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-7350	INJECTION, SOLUTION	714 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-7400	INJECTION, SOLUTION	816 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-9300	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-9350	INJECTION, SOLUTION	714 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	0270-9400	INJECTION, SOLUTION	816 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-725	INJECTION, SOLUTION	510 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-730	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-735	INJECTION, SOLUTION	714 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-740	INJECTION, SOLUTION	816 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-930	INJECTION, SOLUTION	612 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-935	INJECTION, SOLUTION	714 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections
Iomeron	HUMAN PRESCRIPTION DRUG LABEL	1	76381-940	INJECTION, SOLUTION	816 mg	INTRAVASCULAR	Unapproved drug for use in drug shortage	3 sections